$8.13
-0.12-1.45%
After Hours: 4:00 PM EDT
Comments
Loading...
Arcus Biosciences Analyst Ratings and Price Targets | NYSE:RCUS | Benzinga
Arcus Biosciences Inc has a consensus price target of $34.54 based on the ratings of 15 analysts. The high is $70 issued by BTIG on August 23, 2023. The low is $14 issued by Barclays on April 23, 2025. The 3 most-recent analyst ratings were released by Barclays, HC Wainwright & Co., and B of A Securities on April 23, 2025, February 26, 2025, and February 19, 2025, respectively. With an average price target of $18.33 between Barclays, HC Wainwright & Co., and B of A Securities, there's an implied 125.50% upside for Arcus Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
HC Wainwright & Co.
B of A Securities
Morgan Stanley
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Arcus Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/23/2025 | Buy Now | 72.2% | Barclays | Peter Lawson42% | $29 → $14 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 195.2% | HC Wainwright & Co. | Emily Bodnar39% | → $24 | Upgrade | Neutral → Buy | Get Alert |
| 02/19/2025 | Buy Now | 109.1% | B of A Securities | Jason Zemansky72% | $22 → $17 | Maintains | Neutral | Get Alert |
| 02/18/2025 | Buy Now | 121.4% | HC Wainwright & Co. | Emily Bodnar39% | $20 → $18 | Maintains | Neutral | Get Alert |
| 02/18/2025 | Buy Now | 207.5% | Morgan Stanley | Terence Flynn66% | $36 → $25 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 146% | HC Wainwright & Co. | Emily Bodnar39% | $20 → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 10/25/2024 | Buy Now | 256.7% | Barclays | Peter Lawson42% | $25 → $29 | Maintains | Overweight | Get Alert |
| 10/24/2024 | Buy Now | 146% | HC Wainwright & Co. | Emily Bodnar39% | $20 → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 10/21/2024 | Buy Now | 146% | HC Wainwright & Co. | Emily Bodnar39% | → $20 | Initiates | → Neutral | Get Alert |
| 10/08/2024 | Buy Now | 256.7% | Wells Fargo | Eva Fortea Verdejo25% | → $29 | Initiates | → Overweight | Get Alert |
| 10/07/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | → Overweight | Get Alert |
| 10/03/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | → Overweight | Get Alert |
| 10/03/2024 | Buy Now | 269% | Wedbush | Robert Driscoll44% | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2024 | Buy Now | 182.9% | B of A Securities | Jason Zemansky72% | $24 → $23 | Maintains | Neutral | Get Alert |
| 08/09/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 269% | Wedbush | Robert Driscoll44% | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 07/08/2024 | Buy Now | 207.5% | Barclays | Peter Lawson42% | $35 → $25 | Maintains | Overweight | Get Alert |
| 07/05/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | — | Reiterates | → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 441.21% | Truist Securities | Asthika Goonewardene41% | $50 → $44 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 367.4% | Citigroup | Yigal Nochomovitz57% | $36 → $38 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 392% | Morgan Stanley | Terence Flynn66% | $38 → $40 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 269% | Wedbush | Robert Driscoll44% | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 515.01% | Truist Securities | Robyn Karnauskas54% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 269% | Wedbush | Robert Driscoll44% | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 207.5% | B of A Securities | Jason Zemansky72% | $23 → $25 | Maintains | Neutral | Get Alert |
| 01/30/2024 | Buy Now | 269% | Wedbush | Robert Driscoll44% | $36 → $30 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | 416.61% | Mizuho | Mara Goldstein57% | $51 → $42 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 342.8% | Wedbush | Robert Driscoll44% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/13/2023 | Buy Now | 330.5% | Morgan Stanley | Terence Flynn66% | $38 → $35 | Maintains | Overweight | Get Alert |
| 11/08/2023 | Buy Now | 342.8% | Cantor Fitzgerald | Li Watsek40% | $46 → $36 | Maintains | Overweight | Get Alert |
| 10/03/2023 | Buy Now | 527.31% | Mizuho | Mara Goldstein57% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 465.81% | Cantor Fitzgerald | Alethia Young76% | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 465.81% | Cantor Fitzgerald | Alethia Young76% | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 515.01% | Truist Securities | Robyn Karnauskas54% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 182.9% | B of A Securities | Jason Zemansky72% | $21 → $23 | Maintains | Neutral | Get Alert |
| 08/24/2023 | Buy Now | 441.21% | Citigroup | Yigal Nochomovitz57% | $41 → $44 | Maintains | Buy | Get Alert |
| 08/23/2023 | Buy Now | 761.01% | BTIG | Kaveri Pohlman26% | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 527.31% | Mizuho | Mara Goldstein57% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 367.4% | Morgan Stanley | Terence Flynn66% | $40 → $38 | Maintains | Overweight | Get Alert |
| 07/12/2023 | Buy Now | 465.81% | Cantor Fitzgerald | Alethia Young76% | → $46 | Reinstates | Overweight → Overweight | Get Alert |
| 05/26/2023 | Buy Now | 404.31% | Citigroup | Yigal Nochomovitz57% | $40 → $41 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 342.8% | Wedbush | Robert Driscoll44% | → $36 | Reiterates | → Outperform | Get Alert |
| 03/17/2023 | Buy Now | 527.31% | Mizuho | Mara Goldstein57% | → $51 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 392% | Citigroup | Yigal Nochomovitz57% | $42 → $40 | Maintains | Buy | Get Alert |
| 12/21/2022 | Buy Now | 330.5% | Barclays | Peter Lawson42% | $60 → $35 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 416.61% | Citigroup | Yigal Nochomovitz57% | $37 → $42 | Maintains | Buy | Get Alert |
| 11/23/2022 | Buy Now | 355.1% | Citigroup | Yigal Nochomovitz57% | $40 → $37 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 305.9% | B of A Securities | Jason Zemansky72% | → $33 | Initiates | → Neutral | Get Alert |
| 11/03/2022 | Buy Now | 367.4% | SVB Leerink | Daina Graybosch43% | $40 → $38 | Maintains | Outperform | Get Alert |
| 10/11/2022 | Buy Now | 392% | Morgan Stanley | Terence Flynn66% | → $40 | Initiates | → Overweight | Get Alert |
| 08/18/2022 | Buy Now | 392% | Citigroup | Yigal Nochomovitz57% | $48 → $40 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 502.71% | SVB Leerink | Daina Graybosch43% | $66 → $49 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | 515.01% | Truist Securities | Robyn Karnauskas54% | $77 → $50 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | 244.4% | Goldman Sachs | Salveen Richter53% | $48 → $28 | Maintains | Neutral | Get Alert |
| 05/11/2022 | Buy Now | 490.41% | Goldman Sachs | Salveen Richter53% | $43 → $48 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Arcus Biosciences (RCUS) stock?
The latest price target for Arcus Biosciences (NYSE:RCUS) was reported by Barclays on April 23, 2025. The analyst firm set a price target for $14.00 expecting RCUS to rise to within 12 months (a possible 72.20% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcus Biosciences (RCUS)?
The latest analyst rating for Arcus Biosciences (NYSE:RCUS) was provided by Barclays, and Arcus Biosciences maintained their overweight rating.
When was the last upgrade for Arcus Biosciences (RCUS)?
The last upgrade for Arcus Biosciences Inc happened on February 26, 2025 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Arcus Biosciences Inc.
When was the last downgrade for Arcus Biosciences (RCUS)?
There is no last downgrade for Arcus Biosciences.
When is the next analyst rating going to be posted or updated for Arcus Biosciences (RCUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on April 23, 2025 so you should expect the next rating to be made available sometime around April 23, 2026.
Is the Analyst Rating Arcus Biosciences (RCUS) correct?
While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a maintained with a price target of $29.00 to $14.00. The current price Arcus Biosciences (RCUS) is trading at is $8.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
